Cancer remains among the leading causes of death worldwide, partly because conventional treatments cannot fully distinguish the tumor from the host and are limited in managing treatment-resistant forms. However, immunotherapy takes a different approach by directing patient's own immune system to specifically target and eliminate cancer cells. In particular, adoptive cell therapy (ACT) utilizing chimeric antigen receptor (CAR)-engineered T-cells has achieved durable responses in hematological malignancies. The manufacturing of these products, however, rests on a gene-transfer step performed almost exclusively with viral vectors, which are limited by low cargo capacity, long production timelines, regulatory burdens, and considerable costs. Non-viral engineering alternatives like transposon systems promise a faster, safer, and more affordable route to stable transgene insertion. In this project, we attempted to optimize a transposition protocol for the TcBuster™ transposon system in activated human primary T cells using the Neon™ NxT electroporation system, which resulted in approximately 25% CD19-CAR expression at 60% viability. In parallel, a second-generation anti-PSMA CAR under an EF1α promoter was placed between TcBuster-compatible inverted terminal repeats (ITRs) in the backbone of a pUC57 plasmid through seamless cloning, and the final construct was confirmed via Sanger sequencing. Overall, this work established the foundation for a working protocol for TcBuster transposition in primary human T cells using the Neon NxT electroporation platform and provides the custom PSMA-CAR transposon construct, which remains to be tested under the optimized settings.

Cancer remains among the leading causes of death worldwide, partly because conventional treatments cannot fully distinguish the tumor from the host and are limited in managing treatment-resistant forms. However, immunotherapy takes a different approach by directing patient's own immune system to specifically target and eliminate cancer cells. In particular, adoptive cell therapy (ACT) utilizing chimeric antigen receptor (CAR)-engineered T-cells has achieved durable responses in hematological malignancies. The manufacturing of these products, however, rests on a gene-transfer step performed almost exclusively with viral vectors, which are limited by low cargo capacity, long production timelines, regulatory burdens, and considerable costs. Non-viral engineering alternatives like transposon systems promise a faster, safer, and more affordable route to stable transgene insertion. In this project, we attempted to optimize a transposition protocol for the TcBuster™ transposon system in activated human primary T cells using the Neon™ NxT electroporation system, which resulted in approximately 25% CD19-CAR expression at 60% viability. In parallel, a second-generation anti-PSMA CAR under an EF1α promoter was placed between TcBuster-compatible inverted terminal repeats (ITRs) in the backbone of a pUC57 plasmid through seamless cloning, and the final construct was confirmed via Sanger sequencing. Overall, this work established the foundation for a working protocol for TcBuster transposition in primary human T cells using the Neon NxT electroporation platform and provides the custom PSMA-CAR transposon construct, which remains to be tested under the optimized settings.

Evaluation of the TcBuster transposon system delivered by electroporation as a non-viral engineering approach for CAR T-cell generation

AMIRAN, VAHID
2025/2026

Abstract

Cancer remains among the leading causes of death worldwide, partly because conventional treatments cannot fully distinguish the tumor from the host and are limited in managing treatment-resistant forms. However, immunotherapy takes a different approach by directing patient's own immune system to specifically target and eliminate cancer cells. In particular, adoptive cell therapy (ACT) utilizing chimeric antigen receptor (CAR)-engineered T-cells has achieved durable responses in hematological malignancies. The manufacturing of these products, however, rests on a gene-transfer step performed almost exclusively with viral vectors, which are limited by low cargo capacity, long production timelines, regulatory burdens, and considerable costs. Non-viral engineering alternatives like transposon systems promise a faster, safer, and more affordable route to stable transgene insertion. In this project, we attempted to optimize a transposition protocol for the TcBuster™ transposon system in activated human primary T cells using the Neon™ NxT electroporation system, which resulted in approximately 25% CD19-CAR expression at 60% viability. In parallel, a second-generation anti-PSMA CAR under an EF1α promoter was placed between TcBuster-compatible inverted terminal repeats (ITRs) in the backbone of a pUC57 plasmid through seamless cloning, and the final construct was confirmed via Sanger sequencing. Overall, this work established the foundation for a working protocol for TcBuster transposition in primary human T cells using the Neon NxT electroporation platform and provides the custom PSMA-CAR transposon construct, which remains to be tested under the optimized settings.
2025
Evaluation of the TcBuster transposon system delivered by electroporation as a non-viral engineering approach for CAR T-cell generation
Cancer remains among the leading causes of death worldwide, partly because conventional treatments cannot fully distinguish the tumor from the host and are limited in managing treatment-resistant forms. However, immunotherapy takes a different approach by directing patient's own immune system to specifically target and eliminate cancer cells. In particular, adoptive cell therapy (ACT) utilizing chimeric antigen receptor (CAR)-engineered T-cells has achieved durable responses in hematological malignancies. The manufacturing of these products, however, rests on a gene-transfer step performed almost exclusively with viral vectors, which are limited by low cargo capacity, long production timelines, regulatory burdens, and considerable costs. Non-viral engineering alternatives like transposon systems promise a faster, safer, and more affordable route to stable transgene insertion. In this project, we attempted to optimize a transposition protocol for the TcBuster™ transposon system in activated human primary T cells using the Neon™ NxT electroporation system, which resulted in approximately 25% CD19-CAR expression at 60% viability. In parallel, a second-generation anti-PSMA CAR under an EF1α promoter was placed between TcBuster-compatible inverted terminal repeats (ITRs) in the backbone of a pUC57 plasmid through seamless cloning, and the final construct was confirmed via Sanger sequencing. Overall, this work established the foundation for a working protocol for TcBuster transposition in primary human T cells using the Neon NxT electroporation platform and provides the custom PSMA-CAR transposon construct, which remains to be tested under the optimized settings.
CAR T-cell
TcBuster transposon
Electroporation
gene engineering
Immunotherapy
File in questo prodotto:
File Dimensione Formato  
Amiran_Vahid.pdf

Accesso riservato

Dimensione 3.09 MB
Formato Adobe PDF
3.09 MB Adobe PDF

The text of this website © Università degli studi di Padova. Full Text are published under a non-exclusive license. Metadata are under a CC0 License

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.12608/115432